We present a retrospective case series of patients with hyperthyroidism and thyroidcancer. Ourgoalwastolook at theirclinical characteristics and outcomes todetermine which patients would require further investigation. We reviewed the case notesof allpatients with a histopathologic diagnosis ofthyroid cancerand biochemical evidence of hyperthyroidism who had been treated at a thyroid cancer centerfrom January 2006 through October 2013. During that time, 66 patients had been diagnosed with thyroid cancer. Of these, 8 patients {12%)-all women, aged 29 to 87 years (mean: 55.6; median: 50.5)-had biochemical evidence of hyperthyroidism. Among these 8 patients, 4 had an autonomously functioning toxic nodule (AFTN), 3 were diagnosed with Graves disease, and 1 had a toxic multinodulargoiter. Five patients had suspiciousfeatures onpreoperative ultrasonography. All8 patientswere diagnosed with thepapillarytypeof thyroid carcinoma. The mean size of the tumor in the 4 patients with AFTN was significantly larger than it was in those with Graves disease (42.3 ± 23.8 mm vs. 3.8 ± 1.6; p = 0.04). The3 patients with Graves disease allhad incidentallyfound papillary microcarcinoma. Between these two groups, the patients with AFTN had a poorer prognosis; 2 of them had extracapsular invasion and lymph node metastasis, and another died of her disease. We found that the incidence of hyperthyroidism in thyroid cancer patients was relatively high (12%). In contrast to what has previously been reported in the literature, patients with AFTN seem to have more aggressive disease and poorer outcomes than do patients with Graves disease. Any suspicious nodule associated with hyperthyroidism should be evaluatedcarefully.
Introduction
In the earlier part of the 20th century, the literature suggested that hyperthyroidism was protective against thyroid cancer,' However, this belief lost favor as later reports described alowincidence of thyroid cancer-D. IS to 2.5%-among patients with Graves disease.P More recently, however, the trend has reversed over time. In 1970, Shapiro et al reported a rate of 8.7% among patients with hyperthyroidism.' It has been postulated that one explanation for this rise is the fact that patients are now treated with total thyroidectomy rather than the previously accepted subtotal thyroidectomy, and therefore there is a larger specimen available for a more thorough histologic evaluation. ' One of the initial evaluations for assessing a solitary thyroid nodule found on clinical examination or ultrasonography is measurement of the thyroid-stimulating hormone (TSH) level, since it is not uncommon for patients with nodules to be diagnosed with hyperthyroidism." A thyroid nodule can represent a solitary hyperfunctioning nodule (1) in an otherwise normal thyroid gland, (2) within a toxic multinodular goiter, or (3) within Graves disease.' Making the distinction is important since the 2D 15 American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer state that "Since hyperfunctioning nodules rarely harbor malignancy, if one is found that corresponds to the nodule in question, no cytologic evaluation is necessary"
Another area of controversy is the aggressiveness of thyroid cancer in patients with hyperthyroidism. Some authors have described the cancer in these patients as being very aggressive, with metastases to regional lymph nodes and, in rare cases, even causing death.v'? On the other hand, Hales et al concluded that the clinical course in patients with hyperthyroidism is no different from that of euthyroid patients with thyroid cancer. II In this article, we present a case series of patients with hyperthyroidism and thyroid cancer, in which we looked at their clinical characteristics and out-ENT-Ear, Nose & Throat Journal-June 2016 comes to determine which patients required further investigation.
Patients and methods
Our study population was drawn from all patients who were seen at our thyroid cancer center for the management of histopathologically diagnosed thyroid cancer from January 2006 through October 2013; there were 66 such patients. We then retrospectively reviewed the records of those patients who had biochemical evidence ofhyperthyroidism; there were 8 such patients (12%)-all women, aged 29 to 87 years (mean: 55.6; median: 50.5).
In addition to demographic data, we compiled information on the 8 patients' risk factors for thyroid cancer, ultrasonographic findings, the presence or absence of thyrotoxic symptoms, and whether the patient had an autonomously functioning toxic nodule (AFTN), Graves disease, or a toxic multinodular goiter. We also recorded information on cytology and histology.
Statistical analysis was performed with GraphPad Software. Comparisons were carried out by using an unpaired Student t test, and statistical significance was set at p < 0.05.
Results
Three of the 8 patients (38%) had a high risk for thyroid cancer (i.e., a family history of thyroid cancer). Three others had thyrotoxic symptoms. Five patients (63%) had suspicious features on preoperative ultrasonography. Four patients (50%) had AFTN that contained the carcinoma, 3 were diagnosed with Graves disease, and 1 (13%) had a toxic multinodular goiter. All patients were diagnosed with the papillary type of thyroid carcinoma (table) .
The mean size of the tumor in the patients with AFTN was Significantly larger than it was in those with Graves disease (42.3 ± 23.8 mm vs. 3.8 ± 1.6;p =0.04). The 3 patients with Graves disease all had papillary microcarcinoma found incidentally on postoperative histology. The patients with AFTN had a poorer prognosis than did those with Graves disease; 2 of them (patients 3 and 7) had extracapsular invasion and lymph node metastasis, and another (patient 8) died of her disease.
All 3 patients with Graves disease had a category pTlaNO tumor on postoperative histology. In the AFTN group, 2 patients (patients 3 and 7) had a pT3N1a tumor, 1 (patient 4) had a pT3NO tumor, and 1 (patient 8) had a pT4Nlb tumor on postoperative histology. These findings suggested that the AFTN group had more aggressive disease than did the Graves disease group.
Discussion
The incidence of hyperthyroidism in patients with thyroid cancer in our study was 12%,which is relatively high. The literature reports a variable incidence, which ranges as high as 14%. 12, 13 There are several factors that influence the association between thyroid cancer and hyperthyroidism, including the etiology of the hyperthyroidism, the extent of thyroidectomy, geographic variations in the incidence of thyroid cancer, and the extent of the histologic evaluation of the excised thyroid ttssue.v" In our study, we looked at the incidence of hyperthyroidism in patients who were operated on for thyroid cancer, while most reports in the literature looked at the incidence of thyroid cancer in patients with hyperthyroidism.
In our study, we found that all 8 of our patients had the papillary type of thyroid carcinoma. In a review of nomas have also been reported with hyperthyroidism, but they are rare.":" In concordance with the published literature, our study found that the 3 patients with Graves disease had incidental microcarcinoma identified on postoperative histopathologic specimens.' Thyroid cancer was not suspected preoperatively. The clinical significance of these microcarcinomas is not well understood. Kikuchi et al reported that patients with Graves disease and microcarcinomas had an excellent prognosis. I7 Our 4 patients with AFTN had suspicious findings on ultrasonography and cytology that suggested thyroid carcinoma. A review of 60 hyperthyroid patients with thyroid cancer in Greece found that only 12 were operated on because of a preoperative suspicion of thyroid cancer, while the other48 patients had incidental thyroid cancer found on postoperative specimens. '?There was no significant difference in the clinical characteristics at presentation between the patients with the incidental cancers and those whose cancer was suspected preoperatively. These authors also found that only 10 of 17 patients with AFTN had cancer within the toxic nodule; we found that all 4 ofour AFTN patients had the cancer within their toxic nodule.
Cappelli et al reported that thyroid cancer isdiagnosed more frequently in patients with Graves disease than in patients with AFTN or toxic multinodular goiter." On the other hand, Senyurek Giles et al reported a higher prevalence of carcinoma in patients with AFTN or toxic multinodular goiter. [9 The reported probability ofAFTN being associated with thyroid cancer ranges from 1 to 10.3%.20However, the true incidence of thyroid cancer in patients with AFTN may be underreported since large doses of radioiodine are sometimes used to treat the thyrotoxicosis, which also treats the cancer." As mentioned, the American Thyroid Association's 2015 guidelines suggest that since hyperfunctioning nodules rarely harbor malignancy, cytologic evaluation is unnecessary," However, the cytology from our AFTN cases were all suspicious for malignancy.
Belfiore et al reported that patients with Graves disease tend to have larger, more often multifocal, and locally invasive cancers that are more often metastatic to distant sites compared with patients with AFTN. 22 One of the possible reasons for this has been postulated to be the increased production of antibodies to the TSH receptor, which upregulates cell activation and growth-but this theory remains controversial." Other studies have suggested that patients with Graves disease and thyroid cancer do not have more aggressive cancer, '
Our case series demonstrated that AFTNs associated with thyroid cancer are larger and in fact seem to take a more aggressive course. Two of our 4 patients with AFTN exhibited extracapsular invasion and lymph node metastases, and another died of her disease. The staging of the patients in the AFTN group was much more advanced than that in the Graves disease group, indicating that patients in the former group had more aggressive disease. There have been reports that activating mutations of the thyrotropin receptor gene have been identified in AFTN, which might explain our findings, but that theory is also controversial."
To the best of our knowledge, ours is the first study to find that AFTN associated with thyroid cancer has a more aggressive course than thyroid cancer in Graves disease. However, we recognize that there are limitations to our study. Since the number ofcases in our investigation was relatively small, it is difficult to reach meaningful statistical conclusions. Also, there was a significant selection bias in our series, given that we compared patients with AFTN and suspicious ultrasonographic features with Graves patients who had incidentally found microcarcinoma.
Prospective multicenter studies looking at patients with hyperthyroidism and a subsequent diagnosis of thyroid cancer, with particular attention to the selection criteria for surgery, are needed. 
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CMV DNA on 40 dried blood spots of CMV-negative children, and they found that the specificity was 100%. 8 In conclusion, we describe the detection ofCMV DNA in the cochlea of a 6-year-old boy with severe hearing loss due to cCMV infection. We assume from this case that viral replication of CMV after a cCMV infection can persist for several years and that it can be responsible for progressive and/or late-onset hearing loss. In children with severe sensorineural hearing loss of no known etiology, the use of a PCR assay to detect CMV in perilymph at the time of cochlear implantation might lead to the diagnosis of cCMV at a more advanced age.
